Taiyen Biotech CoTPE:1737 83 Altman Z-Score is 3.64 as of Jul. 10, 2026, which is 0% above its 10-year median of 3.63. GuruFocus rates TPE:1737 with a GF Score™ of 83/100 and a GF Value™ of NT$32.09 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,929 Consumer Packaged Goods companies, Taiyen Biotech Co ranks better than 63.14% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.65 is strong.
Taiyen Biotech Co has a Altman Z-Score of 3.64, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Taiyen Biotech Co's Altman Z-Score or its related term are showing as below:
TPE:1737'
s Altman Z-Score Range Over the Past 10 Years
Min: 3.1 Med: 3.63 Max: 4.33
Current: 3.65
During the past 13 years, Taiyen Biotech Co's highest Altman Z-Score was 4.33. The lowest was 3.10. And the median was 3.63.
Taiyen Biotech Co (TPE:1737) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Taiyen Biotech Co Altman Z-Score Related Terms
Taiyen Biotech Co Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1737 vs PG, CL, KVUE: Altman Z-Score Comparison
For the Household & Personal Products subindustry, Taiyen Biotech Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiyen Biotech Co Altman Z-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Taiyen Biotech Co's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Taiyen Biotech Co's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.2174
+
1.4
*
0.0992
+
3.3
*
0.0602
+
0.6
*
4.4037
+
1.0
*
0.4003
=
3.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Taiyen Biotech Co (TPE:1737) has a Altman Z-Score of 3.64 as of Jul. 10, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Taiyen Biotech Co and its competitors. This is near median its historical median of 3.63. Over the past decade, Taiyen Biotech Co's Altman Z-Score has ranged from 3.10 to 4.33. According to the industry distribution chart, Taiyen Biotech Co ranks #711 out of 1929 companies in the Consumer Packaged Goods industry, placing it in the top 36.9%.
Is Taiyen Biotech Co's Altman Z-Score too high?
Taiyen Biotech Co's current Altman Z-Score of 3.64 is near median its 10-year median of 3.63. Over the past 10 years, this metric has ranged from a low of 3.10 to a high of 4.33. The Consumer Packaged Goods industry median Altman Z-Score is 2.85. Taiyen Biotech Co's value of 3.64 is 27.7% above this industry median. Based on the distribution chart, Taiyen Biotech Co ranks #711 out of 1929 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Taiyen Biotech Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Altman Z-Score compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Taiyen Biotech Co ranks #711 out of 1929 companies for Altman Z-Score. This puts Taiyen Biotech Co in the upper half of its industry. The industry median Altman Z-Score is 2.85. Taiyen Biotech Co's value of 3.64 is 27.7% above this benchmark. Historically, Taiyen Biotech Co's own Altman Z-Score has ranged from 3.10 to 4.33 over the past decade. While the company's 10-year median is 3.63 vs. the industry median of 2.85, Taiyen Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Consumer Packaged Goods company?
The median Altman Z-Score among Consumer Packaged Goods companies is 2.85, based on 1,929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiyen Biotech Co's current Altman Z-Score of 3.64 is 27.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Taiyen Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median Altman Z-Score is 2.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiyen Biotech Co's current Altman Z-Score is 3.64, which is near median its own 10-year median of 3.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.09, compared to a current price of NT$31.90 — trading 0.6% below its estimated fair value. The current Altman Z-Score is 3.64, which is near median its 10-year median of 3.63 and 27.7% above the Consumer Packaged Goods industry median of 2.85. Taiyen Biotech Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Altman Z-Score is 3.64 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued.
The current stock price of NT$31.90 is trading 0.6% below its estimated GF Value™ of NT$32.09.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
Altman Z-Score: 3.64 (near median its 10-year median of 3.63)
GF Value™: NT$32.09 vs. price of NT$31.90 (0.6% below fair value)
Industry Position: 27.7% above the Consumer Packaged Goods median (#711 of 1929)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
83GF Score
Get the complete analysis for TPE:1737
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
